Matthew Matasar

35PUBLICATIONS
198CO-AUTHORS
Predictive and prognostic markersHaematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Liquid biopsies
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (35)

|Oct 22, 2026
CAR-HEMATOTOX score to predict risk of poor outcomes with odronextamab in heavily pretreated B-cell non-Hodgkin lymphoma.

|Oct 02, 2026
Pembrolizumab-GVD in relapsed or refractory Hodgkin lymphoma: 5-year update of a multicenter phase 2 trial.

|Sep 10, 2026
Peripheral CD8⁺ T-cell clonality and NK-cell expansion mark early response to mosunetuzumab in indolent B-cell lymphoma.

|Jul 06, 2026
Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Results From the Phase III, Randomized POLARGO Trial.

|Mar 18, 2026
Polatuzumab Vedotin Combined With R-ICE (PolaR-ICE) as Second-Line Therapy in Diffuse Large B-Cell Lymphoma.

Geoffrey Shouse, Matthew Matasar, Lu Chen

|Feb 05, 2026
Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory Richter transformation.

Katharine Louise Lewis, Sarit E Assouline, Ross Ian Baker

Pageof 6

Frequent Collaborators

11 joint publications

Andrew D Zelenetz

9 joint publications

Gilles Salles

8 joint publications

Anita Kumar

8 joint publications

Ariela Noy